Ibrance and Halaven drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Ibrance (palbociclib) and Halaven (eribulin mesylate). Common drug interactions include malignant neoplasm progression among females.

The phase IV clinical study analyzes what interactions people have when they take Ibrance and Halaven. It is created by eHealthMe based on reports of 33 people who take the same drugs from the FDA, and is updated regularly.

What is Ibrance?

Ibrance has active ingredients of palbociclib. eHealthMe is studying from 104,433 Ibrance users. Check the latest studies of Ibrance.

What is Halaven?

Halaven has active ingredients of eribulin mesylate. eHealthMe is studying from 3,881 Halaven users. Check the latest studies of Halaven.

On Oct, 21, 2025

33 people who take Ibrance and Halaven together, and have interactions are studied.

What are the common drug interactions of Ibrance and Halaven, by gender? *:

female:

Malignant neoplasm progression (cancer tumour came back)
Asthenia (weakness)
Neoplasm progression (growth of tumour)
Neutropenia (an abnormally low number of neutrophils)
Metastases to central nervous system (cancer spreads to central nervous system)
Ascites (accumulation of fluid in the abdominal cavity)
Dehydration (dryness resulting from the removal of water)
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection)
Carbohydrate antigen 15-3 increased
Oedema (fluid collection in tissue)

male:

n/a

What are the common drug interactions of Ibrance and Halaven, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Asthenia (weakness)
Headache (pain in head)
Immunosuppression
Meningoencephalitis herpetic (inflammation of the brain and meninges by virus)
Platelet count decreased
Protein total increased
Neoplasm progression (growth of tumour)
Malignant neoplasm progression (cancer tumour came back)
Breast cancer
Metastases to central nervous system (cancer spreads to central nervous system)

50-59:

Breast cancer metastatic
Malignant neoplasm progression (cancer tumour came back)
Metastases to liver (cancer spreads to liver)
Neutropenia (an abnormally low number of neutrophils)
Platelet count decreased
Adenocarcinoma (malignant tumour formed from glandular structures in epithelial tissue)
Anaphylactic reaction (serious allergic reaction)
Ascites (accumulation of fluid in the abdominal cavity)
Breast mass
Carbohydrate antigen 15-3 increased

60+:

Neutropenia (an abnormally low number of neutrophils)
Asthenia (weakness)
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection)
Carbohydrate antigen 15-3 increased
Cholangitis (infection of the bile duct)
Death
Malignant neoplasm progression (cancer tumour came back)
Metastases to central nervous system (cancer spreads to central nervous system)
Metastases to liver (cancer spreads to liver)
Muscle spasms (muscle contraction)

What are the existing conditions these people have? *

Breast Cancer: 12 people, 36.36%
Breast Cancer Metastatic: 9 people, 27.27%
Pain: 4 people, 12.12%
Breast Cancer Female: 4 people, 12.12%
Anaemia (lack of blood): 3 people, 9.09%
Nausea (feeling of having an urge to vomit): 2 people, 6.06%
Metastases To Bone (cancer spreads to bone): 2 people, 6.06%

* Approximation only. Some reports may have incomplete information.

Do you take Ibrance and Halaven?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously